JP2023529892A5 - - Google Patents

Info

Publication number
JP2023529892A5
JP2023529892A5 JP2022575745A JP2022575745A JP2023529892A5 JP 2023529892 A5 JP2023529892 A5 JP 2023529892A5 JP 2022575745 A JP2022575745 A JP 2022575745A JP 2022575745 A JP2022575745 A JP 2022575745A JP 2023529892 A5 JP2023529892 A5 JP 2023529892A5
Authority
JP
Japan
Prior art keywords
soluble
polypeptide
enpp1
enpp3
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022575745A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023529892A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/036494 external-priority patent/WO2021252549A1/en
Publication of JP2023529892A publication Critical patent/JP2023529892A/ja
Publication of JP2023529892A5 publication Critical patent/JP2023529892A5/ja
Pending legal-status Critical Current

Links

JP2022575745A 2020-06-09 2021-06-08 可溶性enpp1又はenpp3タンパク質及びその使用 Pending JP2023529892A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063036833P 2020-06-09 2020-06-09
US63/036,833 2020-06-09
PCT/US2021/036494 WO2021252549A1 (en) 2020-06-09 2021-06-08 Soluble enpp1 or enpp3 proteins and uses thereof

Publications (2)

Publication Number Publication Date
JP2023529892A JP2023529892A (ja) 2023-07-12
JP2023529892A5 true JP2023529892A5 (https=) 2024-06-17

Family

ID=76731053

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022575745A Pending JP2023529892A (ja) 2020-06-09 2021-06-08 可溶性enpp1又はenpp3タンパク質及びその使用

Country Status (14)

Country Link
US (1) US20230313158A1 (https=)
EP (1) EP4162036A1 (https=)
JP (1) JP2023529892A (https=)
KR (1) KR20230042263A (https=)
CN (1) CN116157145A (https=)
AR (1) AR122578A1 (https=)
AU (1) AU2021286502A1 (https=)
BR (1) BR112022024958A2 (https=)
CA (1) CA3181983A1 (https=)
CO (1) CO2023000016A2 (https=)
IL (1) IL298853A (https=)
MX (1) MX2022015772A (https=)
TW (1) TW202214849A (https=)
WO (1) WO2021252549A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3246877A1 (en) * 2022-03-30 2023-10-05 Yale University METHOD AND COMPOSITIONS FOR THE TREATMENT, ALLEVIATION AND/OR PREVENTION OF DIFFUSE IDIOPATHIC SKELETAL HYPEROSTOSIS (DISH)
WO2023196820A2 (en) * 2022-04-04 2023-10-12 Inozyme Pharma, Inc. Treatment of enpp1 deficiency and abcc6 deficiency

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
GB8918616D0 (en) 1989-08-15 1989-09-27 Univ Glasgow Herpes simplex virus type 1 mutant
US20020164782A1 (en) 1999-02-10 2002-11-07 Gregory Richard J. Adenovirus vectors for gene therapy
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
ES2124303T3 (es) 1992-03-25 1999-02-01 Depomed Inc Formas de dosificacion de farmacos orales de liberacion retardada a base de hidroxietilcelulosa.
US5804413A (en) 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
AU3290397A (en) 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
WO1998055107A1 (en) 1997-06-06 1998-12-10 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
AU8605598A (en) 1997-07-31 1999-02-22 University Of Pittsburgh Targeted hsv vectors
HK1050135A1 (zh) 1999-11-02 2003-06-13 Depomed, Inc. 用於促进将药物给予胃的饭後模式药理学诱导
DE60123384T2 (de) 2000-02-04 2007-08-02 DepoMed, Inc., Menlo Park Dosierungsform des typs "hülle und kern" mit einer wirkstofffreisetzung, die sich der nullten ordnung annähert
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
MXPA03011096A (es) 2001-05-29 2004-12-06 Depomed Dev Ltd Metodo para el tratamiento de la enfermedad de reflujo gastroesofagico y la saturacion acida nocturna.
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
AU2005302408B2 (en) 2004-10-28 2012-08-09 The Government of the United States of America as represented by the Department of Veterans Affairs Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
HRP20100638T2 (hr) 2006-11-28 2011-03-31 Proyecto De Biomedicina Cima Viralni vektori i njihova uporaba
US8846603B2 (en) 2010-03-12 2014-09-30 Synageva Biopharma Corp. NPP1 fusion proteins
RU2601154C2 (ru) 2011-03-11 2016-10-27 Синаджива Байофарма Корп Гибридные белки npp1
WO2014126965A2 (en) 2013-02-13 2014-08-21 Yale University Compositions and methods for treating pathological calcification and ossification
ES2523016B1 (es) 2013-05-20 2015-09-09 3P Biopharmaceuticals Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes
GB2526339A (en) 2014-05-21 2015-11-25 Imp Innovations Ltd Lentiviral vectors
EP3194430A1 (en) 2014-09-16 2017-07-26 Universitat Autònoma De Barcelona Adeno-associated viral vectors for the gene therapy of metabolic diseases
EP3967755B1 (en) * 2014-12-19 2024-03-27 Inozyme Pharma, Inc. Soluble npp1 for use in a method for treating pseudoxanthoma elasticum
WO2016156468A1 (en) * 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
EP4414028A3 (en) 2015-05-19 2024-11-27 Yale University Compositions for treating pathological calcification conditions, and methods using same
EP3303373B1 (en) * 2015-05-30 2020-04-08 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
EP3471747A1 (en) * 2016-06-16 2019-04-24 Alexion Pharmaceuticals, Inc. Methods of treating myointimal proliferation
CA3032467A1 (en) 2016-08-05 2018-02-08 Yale University Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
US12134790B2 (en) * 2017-09-27 2024-11-05 Inozyme Pharma, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1)
AU2019267545A1 (en) * 2018-05-08 2020-11-26 Yale University Compositions and methods for reducing progression of nephrolithiasis
CN120383683A (zh) * 2018-08-31 2025-07-29 耶鲁大学 Enpp1多肽及其使用方法
CA3136118A1 (en) 2019-04-05 2020-10-08 Yale University Enpp1 polypeptides and methods of using same

Similar Documents

Publication Publication Date Title
ES2327409T3 (es) Proteinas de fusion fc mejoradas.
US8669350B2 (en) TNF receptor Fc fusion proteins and in vivo methods of use
TWI826358B (zh) 用於治療肌肉萎縮和骨疾病的新型雜合actriib配體陷阱蛋白及其用途與生產方法
CA2983440C (en) Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases
JP2023518434A5 (https=)
AU2020201499A1 (en) Single chain fc fusion proteins
JP5077924B2 (ja) 分泌された三量体受容体類似体及び生物学的活性融合タンパク質を製造するための方法及び組成物
JP2003530093A5 (https=)
JP2016528295A5 (https=)
JP2023529892A5 (https=)
JP2005507637A5 (https=)
KR20160021196A (ko) 안정화된 가용성 예비융합 rsv f 폴리펩타이드
EA019512B1 (ru) Il-6-опосредованная иммунотерапия
CN112236448B (zh) 用包含NC-1-Fc的蛋白寡聚体治疗血管发生、纤维化和癌症相关疾病的手段和方法
JP2014128281A (ja) Pdhおよびfdh酵素を発現する遺伝学的に安定なプラスミド
JP2021535153A5 (https=)
EP2817326A1 (en) Tumour necrosis factor receptor fusion proteins and methods of using the same
JP2021522795A5 (https=)
AU2005259269A1 (en) Process for the purification of IL-18 binding protein
JP2021522793A5 (https=)
JP2023529892A (ja) 可溶性enpp1又はenpp3タンパク質及びその使用
JP2022527557A5 (https=)
US20250041385A1 (en) Modified actrii proteins and methods of use thereof
JP2022525660A (ja) 第ix因子バリアントおよび治療でのその使用
CA3238005A1 (en) Chimeric antigen receptors